Research Analysts Set Expectations for Janux Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:JANX)

Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Stock analysts at HC Wainwright lowered their Q2 2024 EPS estimates for shares of Janux Therapeutics in a report issued on Monday, May 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous estimate […]

Related Keywords

China ,United States ,America ,Engagers Tractr ,Immunomodulators Tracir ,William Blair ,Janux Therapeutics Inc ,China Universal Asset Management Co ,Barclays Plc ,Cantor Fitzgerald ,Allspring Global Investments Holdings ,Cerity Partners ,Nasdaq ,Janux Therapeutics ,Free Report ,Janux Therapeutic ,Get Free Report ,Global Investments Holdings ,Universal Asset Management ,Tumor Activatedt Cell Engagers ,Tumor Activated Immunomodulators ,Janux Therapeutics Daily ,